Novartis Defends Itself Against Kickback Allegations from Former Employee

Novartis Defends Itself Against Kickback Allegations from Former Employee

Source: 
BioSpace
snippet: 

Swiss pharma giant Novartis has found itself at the center of a legal battle that could determine if the company engaged in a research project that was a kickback in disguise.

Former Novartis executive Min Amy Guo has alleged that in 2012, the company initiated a study of breast cancer drug Afinitor with McKesson Corporation. The study of Afinitor, which received approval from the U.S. Food and Drug Administration (FDA) in 2012 as a breast cancer treatment, would have been performed by McKesson and overseen by a client-focused group at Novartis, as opposed to Guo’s group, the Health Economics and Outcomes Research Group, which she helmed.